RxDoctor Payments DataLook up a doctor →

John Notabartolo, PA

Medical · Las Vegas, NVNPI 1023096351

Payments from drug & device makers

$284,097in general payments, 2019–2025

Across 689 payments — averaging $412.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$255K
  • Janssen Scientific Affairs, LLC$16K
  • Arcutis Biotherapeutics, Inc.$7K
  • AbbVie$2K
  • Incyte Corporation$1K
  • Sun Pharmaceutical Industries Inc.$768
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$21,9108%
  • Speaking & faculty fees$195,30369%
  • Travel & lodging$52,04618%
  • Food & beverage$13,9275%
  • Education$9110%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$284,097 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$137,137
Medicare patients
459
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab27$401,487
Skyrizi PenRisankizumab-Rzaa18$376,945
TremfyaGuselkumab20$277,415
Dupixent PenDupilumab34$134,249
Taltz AutoinjectorIxekizumab14$97,304
Cosentyx Sensoready (2 Pens)Secukinumab12$93,560
OpzeluraRuxolitinib Phosphate12$24,012
Betamethasone Dipropionate99$4,802
Clobetasol Propionate93$3,458
Triamcinolone Acetonide190$2,539
Tretinoin28$2,522
Tacrolimus19$2,239
Doxycycline Hyclate77$2,049
Hydroxyzine Hcl133$1,523
Doxycycline Monohydrate55$1,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$254,505$277,41520 claims
Incyte CorporationOpzelura$1,373$24,01212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.

Other medical in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →